Literature DB >> 34725772

Does restaging MRI radiomics analysis improve pathological complete response prediction in rectal cancer patients? A prognostic model development.

Giuditta Chiloiro1, Davide Cusumano1, Paola de Franco2, Jacopo Lenkowicz1, Luca Boldrini1, Davide Carano3, Brunella Barbaro1,3, Barbara Corvari1, Nicola Dinapoli1, Martina Giraffa3, Elisa Meldolesi1, Riccardo Manfredi1,3, Vincenzo Valentini1,3, Maria Antonietta Gambacorta1,3.   

Abstract

PURPOSE: Our study investigated the contribution that the application of radiomics analysis on post-treatment magnetic resonance imaging can add to the assessments performed by an experienced disease-specific multidisciplinary tumor board (MTB) for the prediction of pathological complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC).
MATERIALS AND METHODS: This analysis included consecutively retrospective LARC patients who obtained a complete or near-complete response after nCRT and/or a pCR after surgery between January 2010 and September 2019. A three-step radiomics features selection was performed and three models were generated: a radiomics model (rRM), a multidisciplinary tumor board model (yMTB) and a combined model (CM). The predictive performance of models was quantified using the receiver operating characteristic (ROC) curve, evaluating the area under curve (AUC).
RESULTS: The analysis involved 144 LARC patients; a total of 232 radiomics features were extracted from the MR images acquired post-nCRT. The yMTB, rRM and CM predicted pCR with an AUC of 0.82, 0.73 and 0.84, respectively. ROC comparison was not significant (p = 0.6) between yMTB and CM.
CONCLUSION: Radiomics analysis showed good performance in identifying complete responders, which increased when combined with standard clinical evaluation; this increase was not statistically significant but did improve the prediction of clinical response.
© 2021. Italian Society of Medical Radiology.

Entities:  

Keywords:  Magnetic resonance imaging; Multidisciplinary tumor board; Neoadjuvant chemoradiation; Radiomics; Rectal cancer; Response prediction

Mesh:

Year:  2021        PMID: 34725772     DOI: 10.1007/s11547-021-01421-0

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  35 in total

1.  Practice parameters for the management of rectal cancer (revised).

Authors:  J R T Monson; M R Weiser; W D Buie; G J Chang; J F Rafferty; W Donald Buie; Janice Rafferty
Journal:  Dis Colon Rectum       Date:  2013-05       Impact factor: 4.585

2.  Baseline T Classification Predicts Early Tumor Regrowth After Nonoperative Management in Distal Rectal Cancer After Extended Neoadjuvant Chemoradiation and Initial Complete Clinical Response.

Authors:  Angelita Habr-Gama; Guilherme Pagin São Julião; Joaquim Gama-Rodrigues; Bruna Borba Vailati; Cinthia Ortega; Laura Melina Fernandez; Sérgio Eduardo Alonso Araújo; Rodrigo Oliva Perez
Journal:  Dis Colon Rectum       Date:  2017-06       Impact factor: 4.585

3.  NCCN Guidelines Insights: Rectal Cancer, Version 6.2020.

Authors:  Al B Benson; Alan P Venook; Mahmoud M Al-Hawary; Mustafa A Arain; Yi-Jen Chen; Kristen K Ciombor; Stacey Cohen; Harry S Cooper; Dustin Deming; Ignacio Garrido-Laguna; Jean L Grem; Andrew Gunn; Sarah Hoffe; Joleen Hubbard; Steven Hunt; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A Messersmith; Jeffrey Meyerhardt; Eric D Miller; Mary F Mulcahy; Steven Nurkin; Michael J Overman; Aparna Parikh; Hitendra Patel; Katrina Pedersen; Leonard Saltz; Charles Schneider; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Alyse Johnson-Chilla; Lisa A Gurski
Journal:  J Natl Compr Canc Netw       Date:  2020-07       Impact factor: 11.908

Review 4.  Organ Preservation in Rectal Cancer.

Authors:  Jonathan B Yuval; Hannah M Thompson; Julio Garcia-Aguilar
Journal:  J Gastrointest Surg       Date:  2020-04-20       Impact factor: 3.452

5.  Local excision in rectal cancer patients with major or complete clinical response after neoadjuvant therapy: a case-matched study.

Authors:  M Bushati; S Pucciarelli; N Gennaro; I Maretto; P Toppan; A Perin; E D L Urso; A Bagatella; G Spolverato
Journal:  Int J Colorectal Dis       Date:  2019-11-14       Impact factor: 2.571

6.  Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study.

Authors:  Maxime J M van der Valk; Denise E Hilling; Esther Bastiaannet; Elma Meershoek-Klein Kranenbarg; Geerard L Beets; Nuno L Figueiredo; Angelita Habr-Gama; Rodrigo O Perez; Andrew G Renehan; Cornelis J H van de Velde
Journal:  Lancet       Date:  2018-06-23       Impact factor: 79.321

Review 7.  Rectum-conserving surgery in the era of chemoradiotherapy.

Authors:  F M Smith; D Waldron; D C Winter
Journal:  Br J Surg       Date:  2010-12       Impact factor: 6.939

8.  Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.

Authors:  Angelita Habr-Gama; Rodrigo Oliva Perez; Wladimir Nadalin; Jorge Sabbaga; Ulysses Ribeiro; Afonso Henrique Silva e Sousa; Fábio Guilherme Campos; Desidério Roberto Kiss; Joaquim Gama-Rodrigues
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

9.  Cyclooxygenase-2 in tumor-associated macrophages promotes metastatic potential of breast cancer cells through Akt pathway.

Authors:  Lu Gan; Zhu Qiu; Jing Huang; Yunhai Li; Hongyan Huang; Tingxiu Xiang; Jingyuan Wan; Tianli Hui; Yong Lin; Hongzhong Li; Guosheng Ren
Journal:  Int J Biol Sci       Date:  2016-11-26       Impact factor: 6.580

10.  Could the conservative approach be considered safe in the treatment of locally advanced rectal cancer in case of a clinical near-complete or complete response? A retrospective analysis.

Authors:  Giuditta Chiloiro; Elisa Meldolesi; Martina Giraffa; Nikola Dino Capocchiano; Brunella Barbaro; Claudio Coco; Barbara Corvari; Paola De Franco; Domenico D'Ugo; Sergio Alfieri; Riccardo Manfredi; Vincenzo Valentini; Maria Antonietta Gambacorta
Journal:  Clin Transl Radiat Oncol       Date:  2021-02-25
View more
  4 in total

1.  Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a radiomic model to predict tumor grade.

Authors:  Giuditta Chiti; Giulia Grazzini; Federica Flammia; Benedetta Matteuzzi; Paolo Tortoli; Silvia Bettarini; Elisa Pasqualini; Vincenza Granata; Simone Busoni; Luca Messserini; Silvia Pradella; Daniela Massi; Vittorio Miele
Journal:  Radiol Med       Date:  2022-08-02       Impact factor: 6.313

2.  Ability of Delta Radiomics to Predict a Complete Pathological Response in Patients with Loco-Regional Rectal Cancer Addressed to Neoadjuvant Chemo-Radiation and Surgery.

Authors:  Valerio Nardone; Alfonso Reginelli; Roberta Grassi; Giovanna Vacca; Giuliana Giacobbe; Antonio Angrisani; Alfredo Clemente; Ginevra Danti; Pierpaolo Correale; Salvatore Francesco Carbone; Luigi Pirtoli; Lorenzo Bianchi; Angelo Vanzulli; Cesare Guida; Roberto Grassi; Salvatore Cappabianca
Journal:  Cancers (Basel)       Date:  2022-06-18       Impact factor: 6.575

Review 3.  The Role of Magnetic Resonance Enterography in Crohn's Disease: A Review of Recent Literature.

Authors:  Marysol Biondi; Eleonora Bicci; Ginevra Danti; Federica Flammia; Giuditta Chiti; Pierpaolo Palumbo; Federico Bruno; Alessandra Borgheresi; Roberta Grassi; Francesca Grassi; Roberta Fusco; Vincenza Granata; Andrea Giovagnoni; Antonio Barile; Vittorio Miele
Journal:  Diagnostics (Basel)       Date:  2022-05-15

4.  Radiomics and Machine Learning Analysis Based on Magnetic Resonance Imaging in the Assessment of Colorectal Liver Metastases Growth Pattern.

Authors:  Vincenza Granata; Roberta Fusco; Federica De Muzio; Carmen Cutolo; Mauro Mattace Raso; Michela Gabelloni; Antonio Avallone; Alessandro Ottaiano; Fabiana Tatangelo; Maria Chiara Brunese; Vittorio Miele; Francesco Izzo; Antonella Petrillo
Journal:  Diagnostics (Basel)       Date:  2022-04-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.